Prosecution Insights
Last updated: November 20, 2026
Application No. 18/818,959

PROXIMAL EMBOLIC PROTECTION DEVICE FOR CAROTID STENTING

Non-Final OA §102§103§112
Filed
Aug 29, 2024
Priority
Sep 01, 2023 — provisional 63/536,244
Examiner
DARB, HAMZA A.
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Boston Scientific Corporation
OA Round
1 (Non-Final)
74%
Grant Probability
Favorable
1-2
OA Rounds
1y 1m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
410 granted / 554 resolved
+4.0% vs TC avg
Strong +31% interview lift
Without
With
+30.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
44 currently pending
Career history
633
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
50.6%
+10.6% vs TC avg
§102
17.0%
-23.0% vs TC avg
§112
25.1%
-14.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 554 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Objections Claims 1, 10, 13 are objected to because of the following informalities: Please spell out “its” in line 4 of claim 1 to what it is referring to. Please spell out “its” in line 3 of claim 10 to what it is referring to. Please spell out “its” in line 5 of claim 13 (and repeated in line 13 of claim 13) to what it is referring to. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 2, 7-8, 10-20 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 2 recites the limitation "the distal catheter extension" in line 2. There is insufficient antecedent basis for this limitation in the claim. Claim 7 recites the limitation "the catheter body" in line 1. There is insufficient antecedent basis for this limitation in the claim. Claim 10 recites the limitation "the distal region of the catheter body" in line 6. There is insufficient antecedent basis for this limitation in the claim. Also, it is unclear if it is referring to the distal end of the proximal catheter segment or it is referring to the distal end of the distal catheter segment or it is referring to new limitation. For the purpose of examination, the examiner will interpret the limitation as it is referring to the distal end of the proximal catheter segment. Claim 10 recites the limitation "the distal region of the catheter body" in line 10. There is insufficient antecedent basis for this limitation in the claim. Also, it is unclear if it is referring to the distal end of the proximal catheter segment or it is referring to the distal end of the distal catheter segment or it is referring to new limitation. For the purpose of examination, the examiner will interpret the limitation as it is referring to the distal end of the proximal catheter segment. Claim 13 recites the limitation "over the catheter body" in line 15. it is unclear if it refers to the catheter body of the first catheter or second catheter or it is referring to new limitation. For the purpose of examination, the examiner will interpret the limitation as it is referring to the catheter body of the second catheter Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 13-20 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Ho et al. (US 20120022426 A1) (“Ho”). Re claim 13, Ho discloses a reverse flow medical device (Fig. 1-13, ¶0016, abstract) combination for performing carotid artery stenting (Fig. 13, 1310), the reverse flow medical device combination comprising: a first catheter (110) including: a catheter body extending from a proximal region (lower region of 110) to a distal region (region of 610 and top end of 110) including a distal end (top end of 110), the catheter body adapted to terminate with its distal end within a common carotid artery (CCA, Fig. 10-13); a working lumen (lumen of 110, ¶0019) extending through the catheter body and terminating at the distal end of the catheter body (Fig. 10-13); a first inflatable balloon (610) secured within the distal region of the catheter body of the first catheter and adapted when inflated to occlude the CCA (Fig. 10-13, ¶0026); and a second catheter (210) including: a catheter body extending from a proximal region (lower portion of 210) to a distal region (region at 910, 1120) including a distal end ( top end of 210), the catheter body adapted to terminate with its distal end within an internal carotid artery (ICA, Fig. 10-13 ¶0029); an expandable stent (1310) disposed over the catheter body (¶0030), a second inflatable balloon (910) secured within the distal region of the catheter body of the second catheter (Fig. 13); a blood lumen ( lumen from 110 to 120, ¶0029) extending through the catheter body to a position distal of the second inflatable balloon in order to allow antegrade blood flow from a position proximal of the first inflatable balloon to a position distal of the second inflatable balloon (¶0029). Re claim 14, Ho discloses wherein the second catheter further comprises a stent deployment sheath (520) that is adapted to be withdrawn proximally in order to deploy the stent (¶0029-¶0030). Re claim 15, Ho discloses wherein the second catheter further comprises a post-stenting dilation balloon (1210, ¶0030). Re claim 16, Ho discloses wherein the second catheter further comprises one or more flushing ports disposed proximal of the second inflatable balloon (1220, ¶0030). Re claim 17, Ho discloses wherein the second catheter is adapted to extend coaxially with the first catheter (Fig, 12). Re claim 18, Ho discloses wherein the second catheter is adapted to extend within the working lumen of the first catheter ( the second catheter is capable to be extended within the working lumen). Re claim 19, Ho discloses wherein the second catheter is adapted to extend next to the first catheter (Fig, 12). Re claim 20, Ho discloses wherein the first inflatable balloon comprises a lumen ( lumen of the balloon 610 for 110) extending therethrough adapted to accommodate the first catheter within the lumen (Fig. 10-13). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1-12 is/are rejected under 35 U.S.C. 103 as being unpatentable over Coppi (US 20050273051 A1) in view of Ho. Re claim 1, Coppi discloses a reverse flow catheter for performing carotid artery stenting (Fig. 1-6, ¶0023, abstract), the reverse flow catheter comprising: a proximal catheter segment ( segment from 3 to 4) extending from a proximal region (5) to a distal region including a distal end ( balloon region and distal end 4), the proximal catheter segment adapted to terminate with its distal end within a common carotid artery (CCA) (Fig. 4, artery 10); a distal catheter segment ( 11) extending from a proximal end (lower end of 11) to a distal region including a distal end (balloon 12 region and top end, Fig. 4), the distal catheter segment extending distally from the distal end of the proximal catheter segment (Fig, 4), the distal catheter segment adapted to terminate within an external carotid artery (ECA) ( vessel 210, Fig. 4, ¶0066); a working lumen ( lumen 2, Fig. 4) extending through the proximal catheter segment and terminating at the distal end of the proximal catheter segment (Fig. 2); a CCA occlusion balloon (9, Fig, 4, ¶0058) secured within the distal region of the proximal catheter segment (Fig, 4); an ECA occlusion balloon (12) secured within the distal region of the distal catheter segment (Fig. 4. ¶0067); a first shunt port (lower port 20 of conduit 7, Fig. 5) disposed within the proximal catheter segment proximal of the CCA occlusion balloon (Fig. 5); a second shunt port ( top port of the conduit 7, Fig. 5) disposed within the distal catheter segment distal of the ECA occlusion balloon ( Fig. 5) and a shunt lumen extending between the first shunt port and the second shunt port ( 7), but it fails to disclose that the shunt lumen is in order to allow antegrade blood flow from proximal of the CCA occlusion balloon to distal of the ECA occlusion balloon. However, Ho discloses a catheter (Fig, 12) and wherein a shunt lumen extending between the first shunt port (1110) and the second shunt port ( 1120) is used in order to allow antegrade blood flow from proximal of the CCA occlusion balloon (610) to distal of the occlusion balloon (910, ¶0029, ¶0006). Thus, it would have been prima facie obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modify the shut lumen of Coppi so that the shunt lumen is used in order to allow antegrade blood flow from proximal of the CCA occlusion balloon to distal of the ECA occlusion balloon as taught by Ho for the purpose of maintaining blood flow from proximal of the first inflatable member to distal of the second inflatable member through the catheter part of the distal balloon catheter while isolating the branch vessel (Ho, ¶0006). Re claim 2, Coppi discloses wherein the shunt lumen extends through part of the proximal catheter segment and through the distal catheter extension (Fig. 5). Re claim 3, Coppi fails to discloses wherein the shunt lumen comprises an ovoid-shaped shunt lumen. However, Ho discloses a catheter (Fig, 1) and wherein the lumen (110) comprises an ovoid-shaped lumen (Fig. 1). Thus, it would have been prima facie obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modify the shut lumen of Coppi so that the shunt lumen comprises an ovoid-shaped shunt lumen.as taught by Ho for the purpose of maintaining blood flow from proximal of the first inflatable member to distal of the second inflatable member through the catheter part of the distal balloon catheter while isolating the branch vessel (Ho, ¶0006). Re claim 4, Coppi discloses further comprising an inflation lumen (6, 8) extending to and fluidly coupled with the CCA occlusion balloon (Fig.3-5). Re claim 5, Coppi discloses wherein the inflation lumen also extends to and is fluidly coupled with the ECA occlusion balloon (Fig. 3-5). Re claim 6, Coppi discloses wherein the working lumen is adapted to accommodate retrograde blood flow therethrough (lumen 2 is capable to accommodate retrograde blood flow therethrough). Re claim 7, Coppi discloses wherein the catheter body has an 8 French outer diameter (¶0026, diameters with different measurement than 13-14 French can be used). Re claim 8, Coppi discloses, wherein the working lumen has a 6 French inner diameter (less than 7 French ¶0055). Re claim 9, Coppi discloses wherein the working lumen is adapted to accommodate a stent delivery catheter extended through the working lumen and into the interior carotid artery (ICA) (Fig. 4, ¶0069). Re claim 10, Coppi discloses a catheter (Fig. 1-6, ¶0023, abstract), comprising: a proximal catheter segment (segment from 3 to 4) extending from a proximal region (5) to a distal region including a distal end (ballon region and distal end 4), the proximal catheter segment adapted to terminate with its distal end within a common carotid artery (CCA) (Fig. 4, artery 10), the proximal catheter segment having an 8 French outer diameter (¶0026 as the outer diameter can be less than 12 and other size can be used); a distal catheter segment extending (11) from a proximal end ( lower end of 11) to a region including a distal end ( region of the balloon 12 and top end of 11, Fig. 4-5), the distal catheter segment extending distally from the distal end of the catheter body (Fig, 4-5), the distal catheter segment adapted to terminate within an external carotid artery (ECA) ()vessel 210, Fig. 4, ¶0066); a working lumen (2) extending through the proximal catheter segment and terminating at the distal end of the proximal catheter segment (Fig. 1-5), the working lumen having a 6 French inner diameter ( up to 7 French, ¶0055); a CCA occlusion element (9)secured within the distal region of the catheter body (Fig. 1-5); an ECA occlusion element (12) secured within the distal region of the distal catheter segment (Fig. 1-5); and a blood shunt path (7) extending from a position proximal of the CCA occlusion element ( lower opening of 7, Fig. 5) to a position distal of the ECA occlusion element (upper opening of 7), but it fails to disclose that the shunt path is used in order to allow antegrade blood flow from proximal of the inflatable CCA occlusion balloon to distal of the inflatable ECA occlusion balloon. However, Ho discloses a catheter (Fig, 12) and wherein a shunt lumen extending between the first shunt port (1110) and the second shunt port ( 1120) is used in order to allow antegrade blood flow from proximal of the CCA occlusion balloon (610) to distal of the occlusion balloon (910, ¶0029, ¶0006). Thus, it would have been prima facie obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modify the shut lumen of Coppi so that the shunt path is used in order to allow antegrade blood flow from proximal of the inflatable CCA occlusion balloon to distal of the inflatable ECA occlusion balloon as taught by Ho for the purpose of maintaining blood flow from proximal of the first inflatable member to distal of the second inflatable member through the catheter part of the distal balloon catheter while isolating the branch vessel (Ho, ¶0006). Re claim 11, Coppi discloses a proximal blood shunt port ( lower opening of 11, Fig. 5) fluidly coupled with a proximal end of the blood shunt path (7); and a distal blood shunt port ( top opening of 7) fluidly coupled with a distal end of the blood shunt path (Fig. 1-5). Re claim 12, Coppi discloses wherein the working lumen is adapted to accommodate retrograde blood flow through the working lumen simultaneously with a stent delivery catheter being advanced through the working lumen (lumen 2 is capable to accommodate the retrograde blood flow and delivery the stent catheter15 at the same time, Fig. 4). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to HAMZA A. DARB whose telephone number is (571)270-1202. The examiner can normally be reached 8:00-5:00 M-F (EST). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Chelsea Stinson can be reached at (571) 270-1744. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /HAMZA A DARB/Examiner, Art Unit 3783 /CHELSEA E STINSON/Supervisory Patent Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Aug 29, 2024
Application Filed
Oct 14, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778754
STIMULATION OF PENIS ERECTION
2y 4m to grant Granted Nov 03, 2026
Patent 12773526
VASCULAR ACCESS CATHETER
3y 11m to grant Granted Oct 27, 2026
Patent 12766294
CATHETER SYSTEM HAVING A NEEDLE RETRACTION MECHANISM
3y 10m to grant Granted Oct 20, 2026
Patent 12758744
CATHETER DEVICE
3y 7m to grant Granted Oct 13, 2026
Patent 12746367
PERIPHERAL INTRAVENOUS CATHETER ASSEMBLY HAVING AN EXTENSION SET
7y 1m to grant Granted Sep 29, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
74%
Grant Probability
99%
With Interview (+30.8%)
3y 4m (~1y 1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 554 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month